At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Open-label, Randomized Trial in Treatment-naive HIV-1-infected Subjects to Determine the Antiviral Activity of 14 Days of Monotherapy With 4 Different Dose Regimens of TMC310911 Coadministered With Ritonavir
In Brief
A Phase 2 clinical trial evaluating TMC310911 75 mg twice daily, TMC310911 150 mg twice daily, and 4 other interventions for Human Immunodeficiency Virus Type 1. Completed, enrolled 33 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the antiviral activity as measured by the change in viral load from baseline in the 14 days following initiation of treatment with 4 different dose regimens of TMC310911 co-administered with ritonavir.
Study Details
Timeline
Interventions
TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14